Oligonucleotide Drug CDMO Market Growth Analysis Report by Type (API, Preparation), by applications (SME Pharmaceutical Company, Large Pharmaceutical Company) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Global Forecast to 2030
Oct-2024 Formats | PDF | Category: Pharma and Healthcare | Delivery: 24 to 72 Hours
Oligonucleotide Drug CDMO Market Overview
The Oligonucleotide Drug CDMO Market refers to the various contract development and manufacturing organizations (CDMOs) that offer targeted services such as research, process development, analytical testing, scale-up, manufacturing, packaging and regulatory support for this class of therapeutic. These services and technologies enable pharmaceutical/biotech companies developing the class of antisense oligonucleotides (ASO), small interfering RNA (siRNA), messenger RNA (mRNA), aptamer, microRNA (miRNA) and other nucleic-acid therapies. CDMOs are able to provide access to emerging synthesis technologies, solid support GMP manufacturing and quality assurance delivered through an integrated supply chain; thus enabling fast bringing to market and reducing initial capital investment requirements.
For the past decade, the field has been significantly revolutionized by the rapid development of RNA therapeutics, gene-silencing modalities, and personalized medicine. The successful commercialization of multiple oligonucleotide drugs not only proved the therapeutics value of nucleic acid based drugs but also attracted more investments for research and clinical studies. Meanwhile, more and more drugmakers outsourced complex manufacturing to contract manufacturing organizations with professional ability in large-scale synthesis, purification, conjugation, and formulation of oligonucleotide drugs. Innovations of solid phase synthesis chemistry, automation manufacturing system, high-throughput purification system, and sophisticated analytical platform enhanced the manufacturing efficiency, output, and Quality.
The increasing demand for personalized medicine and targeted therapy is a significant factor promoting the growth of the Oligonucleotide Drug CDMO Market. The escalation of rare genetic disease, neurological diseases, cardiovascular disease, infectious disease, oncology indications has led to an increase in the development of RNA therapeutics. There is a rise in the number of oligonucleotide drugs being added to the pipeline, which, in turn, is driven by the increased need for contract manufacturing partners to support preclinical, clinical, and commercial requirements.
Technology continues to evolve as the competitive environment advances. Given the improvements in phosphoramidite chemistry, automated synthesis, arraying, LNP delivery systems, continuous manufacturing and automation, with advanced purification technology, have already established a substantial increase in manufacturing efficiency, and at a significant reduction in cost. Digital manufacturing and automation, data monitoring and analysis, process optimization using artificial intelligence and continuous manufacturing have all improved overall process and regulatory compliance in CDMO facilities.
Manufacturers are required to demonstrate through rigorous regulatory standards defined by global health agencies the knowledge, sophistication, and level of quality control, GMP, process validation, contamination control and tracing of that product. As regulations continue to develop, CDMOs are responding by developing comprehensive quality management systems, purchasing advanced manufacturing technology and employing regulatory addition expertise to facilitate worldwide approvals and launches.
North America is still the dominant regional market in the field of CDMO owing to its well- developed biotechnology environment, high investment in pharmaceutical R&D, an extensive CDMO network, and a beneficial regulatory framework. Europe still experiences strong growth owing to an expanding biologics manufacturing infrastructure, government supported life sciences research, and an uptrend in outsourcing activities. Conversely, the Asia-Pacific market is the fastest-growing regional market owing to an expanding infrastructure in pharmaceutical manufacturing, a cost-efficient manufacturing base, rapid growth of clinical research activities, and rising biotechnology investments in leading markets such as China, Japan, South Korea and India.
With more regulatory approvals for RNA-based therapies, and pharmaceutical companies under pressure to find adaptable and scalable production solutions, the Oligonucleotide Drug CDMO Market is set for healthy long-term growth. Further outsourcing, ongoing improvements in technology relating to nucleic acid manufacturing, an uptrend in new therapeutic uses for RNA drugs, and higher levels of overall investment in biopharmaceutical manufacturing facilities, will further fuel opportunities for CDMOs.
ATTRIBUTE | DETAILS |
Study period | 2023-2030 |
Base year | 2023 |
Estimated year | 2023 |
Forecasted year | 2024-2030 |
Historical period | 2019-2023 |
Unit | Value (USD Billion) |
Segmentation | By Type , Application and Region |
By Type | API Preparation |
by Application | SME Large |
By Region | North America Asia Pacific Europe South America Middle East Asia |
The Oligonucleotide Drug CDMO market is segmented as below:
By Company
- Siemens
- ABB
- Robert Bosch GmbH
- Schneider Electric
Segment by Type
- API
- Preparation
Segment by Application
- SME Pharmaceutical Company
- Large Pharmaceutical Company
Global Oligonucleotide Drug CDMO Market Regional and Country-wise Analysis
North America (U.S., Canada, Mexico)
Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)
Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)
Latin America (Brazil, Rest of Latin America)
The Middle East and Africa (Turkey, GCC, Rest of the Middle East and Africa)
Rest of the World….
Each chapter of the report provides detailed information for readers to further understand the Oligonucleotide Drug CDMO market:
Chapter 1: Introduces the report scope of the Oligonucleotide Drug CDMO report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2023-2030)
Chapter 2: Detailed analysis of Oligonucleotide Drug CDMO manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2019-2024)
Chapter 3: Provides the analysis of various Oligonucleotide Drug CDMO market segments by Type, covering the market size and development potential of each market segment, to help readers find the Oligonucleotide Drug CDMO market in different market segments. (2023-2030)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the Oligonucleotide Drug CDMO market in different downstream markets.(2023-2030)
Chapter 5: Sales, revenue of Oligonucleotide Drug CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2023-2030)
Chapter 6: Sales, revenue of Oligonucleotide Drug CDMO in country level. It provides sigmate data by Type, and by Application for each country/region.(2023-2030)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2019-2024)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Benefits of purchasing For Insights Consultancy Research report:
Competitive Analysis: For Insights Consultancy Research provides in-depth Oligonucleotide Drug CDMO competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.
Industry Analysis: For Insights Consultancy Research provides Oligonucleotide Drug CDMO comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market
trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.
Market Size: For Insights Consultancy Research provides Oligonucleotide Drug CDMO market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.
Buy this Report with 20 % Discount
Frequently Asked Questions
What is the expected growth rate of the Oligonucleotide Drug CDMO market over the next 7 years?
Oligonucleotide Drug CDMO Market is estimated to increase at a CAGR of 16% by 2030.
Which region is dominating in the Oligonucleotide Drug CDMO market?
The Oligonucleotide Drug CDMO market is experiencing significant growth, with North America currently dominating the market.
Who are the major key players in the Oligonucleotide Drug CDMO market?
The Oligonucleotide Drug CDMO market is a competitive space with key players such as Bachem, WuXi TIDES, Ajinomoto Co, Waters, AGC Biologics, Merck KGaA, EUROAPI, CordenPharma, Cytiva, TriLink BioTechnologies, Medicilon, General Biol, BioSpring, Bio-Synthesis Inc, Aurisco, Suzhou Olipharma Co.,Ltd, Porton, RIBOPharm.
For Insights Consultancy Research Features of Customized Research Services
- FIC Research have an expert team of analysts which is a blend of fresh and experienced talent from various end-use industries. This permits us to successfully accomplished interdisciplinary projects.
- FIC Research is offering customized research services at attractive prices. Our clients should rely on us for high-quality customized reports.
- FIC Research offer creative and innovative research methodologies which help our clients to make their business strategies.
- FIC Research is committed to provide top quality customized reports which will be helpful for our clients to deal with unique challenges.
Contact us-https://forinsightsconsultancy.com/contact-us/
Related Report
CRISPR Market
https://www.forinsightsconsultancy.com/reports/crispr-market
MRNA Vaccine Drugs Development Services Market
https://www.forinsightsconsultancy.com/reports/mrna-vaccine-drugs-development-services-market
Table of Contents
Request for TOC- https://forinsightsconsultancy.com/contact-us/
Select PDF License
Single User: $3499
Multiple Users: $4499
Corporate Users: $5499
